News | Left Atrial Appendage (LAA) Occluders | October 13, 2016

SentreHeart Announces First Clinical Use of Eclipse Surgical LAA Closure Device

First procedures conducted in Krakow, Poland

SentreHeart, Eclipse Surgical Device, left atrial appendage, LAA closure, first clinical use, Poland

October 13, 2016 — SentreHeart Inc. announced this week it has treated the first patients using the Eclipse Surgical Device, which is approved and CE Marked in Europe for left atrial appendage (LAA) closure. Krzysztof Bartus, M.D., Ph.D., and associate professor of the Jagiellonian University, Department of Cardiovascular and Transplant Surgery in Krakow, Poland performed the procedures.

According to Bartus, “The procedures went exceedingly well. Complete closure was achieved in all cases. The ultra-low profile of the Eclipse improves visualization during placement, is easy to use and unlike other surgical solutions, does not require excessive grasping or manipulation of the left atrial appendage to close around its base.”

The Eclipse enables remote delivery of a 50mm pre-tied suture loop in a controlled and precise manner with immediate and complete LAA closure.

For more information: www.sentreheart.com

Related Content

Edwards Intuity Elite sutureless aortic valve, first implants in Connecticut, WCHN, Western Connecticut Health Network
News | Cardiovascular Surgery| February 16, 2017
Western Connecticut Health Network (WCHN) cardiothoracic surgeons Cary Passik, M.D., and Robert Gallagher, M.D., were...
Medtronic, expanded indication, Freezor Xtra Cryoablation Catheter, AVNRT, atrioventricular nodal re-entrant tachycardia
Technology | Ablation Systems| February 16, 2017
Medtronic plc announced the U.S. Food and Drug Administration (FDA) has approved its Freezor Xtra Cryoablation Catheter...
heart team, hybird OR, structural heart team

The heart team approach was first used on a large scale in the CoreValve and Sapien TAVR trials and helped lead to excellent outcomes in high-risk patients.

Feature | Hybrid OR| February 15, 2017 | Dave Fornell
In the current era of healthcare reform and the push toward evidence-based medicine to both lower costs and improve p
Xarelto, rivaroxaban, COMPASS study, ends early,
News | Antiplatelet and Anticoagulation Therapies| February 09, 2017
February 9, 2017 — Janssen Research & Development LLC (Janssen) announced that the Phase 3 COMPASS trial is stopp
Ohio State, Wexner Medical Center, keeping human hearts alive, track abnormal beats, reanimate, Vadim Fedorov

Part of a donated human heart is reanimated and recorded with four high-definition optic cameras in a laboratory at The Ohio State University Wexner Medical Center. Researchers keep the heart tissue alive to look for the causes of irregular heartbeats in cases of persistent atrial fibrillation. Image courtesy of The Ohio State University Wexner Medical Center.

News | EP Lab| February 01, 2017
Researchers have developed a technique that allows them to revive parts of human hearts in the laboratory for up to 12...
CardioFocus, HeartLight Excalibur Balloon, 22nd Annual AF Symposium, atrial fibrillation, initial clinical evaluation
News | Ablation Systems| January 25, 2017
CardioFocus Inc. recently announced the initial clinical evaluation of the HeartLight Excalibur Balloon, a next-...
congenital heart disease, CHSD, Society of Thoracic Surgeons, public reporting, parent preferences
News | Congenital Heart| January 25, 2017
Survival statistics, surgeon-specific experience and complication rates are the types of information most wanted by...
SAVR, surgical aortic valve replacement, elderly patients, aortic stenosis, Society of Thoracic Surgeons, clinical study
News | Structural Heart| January 25, 2017
Elderly patients with aortic stenosis (AS) and medium surgical risk experienced better than expected results after...
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents| January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
atrial fibrillation patients, warfarin therapy, medication adherence, University of Michigan study, JAMA Cardiology
News | Antiplatelet and Anticoagulation Therapies| January 11, 2017
For patients with atrial fibrillation, the most common form of heart arrhythmia, a main goal of treatment is stroke...
Overlay Init